Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds


Physical exercise program in lung cancer patients with non-operable disease undergoing palliative treatment

In cooperation with the Thoracic Oncology Clinic for Thoracic Diseases/University of Heidelberg.


Principal Investigators: Prof. Dr. Michael Thomas, Dr. Simone Hummler, Dr. Joachim Wiskemann
Co-Principal Investigators: PD Dr. Steins, Prof. Dr. Philipp Beckhove, Prof. Dr. Dr. Ulrich Abel, Prof. Dr. Karen Steindorf, Prof. Dr. Cornelia Ulrich


The POSITIVE Study (Part III) is a randomized-controlled phase III trial in patients with stage IIIB/IV non-small cell lung cancer (NSCLC). The aim is to evaluate the effects of a 12-/24-week exercise intervention program (EIP) on quality of life, physical functioning and immune function parameters. Eligible patients (n=250) will be enrolled in the Clinic for Thoracic Diseases, Heidelberg, over a time period of two years and followed up for a total of 12 months.

Patients will be randomized either to EIP plus Care Management Phone Calls (CMPC) versus CMPC alone. Besides a proper symptom and side effect management CMPC ensures the potential influence of social contacts that can be anticipated for the patients in the intervention group.

Our primary aims are to investigate whether a partly supervised (in- and outpatient) and partly home-based endurance and resistance training improves quality of life and lowers levels of fatigue (evaluation via the standardized and validated questionnaires FACT-L and MFI). In addition we propose to evaluate the effects of EIP on tumor specific immune responses. Biomarkers of immune function will be measured by cellular immunity and cytokine and chemokine panels.

Further secondary outcomes include measurement of anxiety, depression and demoralization, physical performance parameters (e.g. improvement in walk distance, muscle strength), as well as overall and progression free survival analyses.

Our study builds on a previous feasibility study of a 8 weeks exercise intervention trial in patients with advanced NSCLC with the results being utilized in the design of the here proposed trial.

We hypothesize that patients randomized in the EIP group will show improved QoL and reduced fatigue, as well as improved physical functioning and increased tumor specific immune responses.

The study is supported by the German Cancer Aid.

Current status

Recruitment of the POSITIVE study (Part III) was completed in December 2016 with 232 patients.


Prof. Dr. Karen Steindorf
phone: +49 6221 42 2351


Wiskemann J, Hummler S, Diepold C, Keil M, Abel U, Steindorf K, Beckhove P, Ulrich CM, Steins M, Thomas M: POSITIVE study: physical exercise program in non-operable lung cancer patients undergoing palliative treatment. BMC Cancer 16, 499, 2016.

to top
powered by webEdition CMS